PMID- 27943605
OWN - NLM
STAT- MEDLINE
DCOM- 20180409
LR  - 20220317
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 37
IP  - 7
DP  - 2017 Jul
TI  - Efficacy and safety of direct-acting antivirals-based antiviral therapies for 
      hepatitis C virus patients with stage 4-5 chronic kidney disease: a 
      meta-analysis.
PG  - 974-981
LID - 10.1111/liv.13336 [doi]
AB  - BACKGROUND & AIMS: The aim of this study was to assess the efficacy and safety of 
      direct-acting antivirals (DAA)-based antiviral therapies for HCV patients with 
      stage 4-5 chronic kidney disease. METHODS: We conducted a systematic literature 
      search in PubMed, EMBASE, Web of Science, and CENTRAL on the Cochrane Library 
      without time and language limitations. The search strategy used was "(End stage 
      renal disease OR chronic kidney failure OR severe renal impairment OR chronic 
      kidney disease OR dialysis) AND (sofosbuvir OR simeprevir OR grazoprevir OR 
      elbasvir OR ombitasvir OR paritaprevir OR ritonavir OR dasabuvir OR daclatasvir 
      OR asuparevir OR direct-acting antiviral OR DAA)". Sustained virologic response 
      at 12 weeks after the end of treatment (SVR12), adverse events (AEs) and/or 
      serious adverse events (SAEs) with 95% confidence intervals (CI) were pooled. 
      RESULTS: Eleven studies, comprising a total of 264 patients were included for our 
      meta-analysis. The pooled SVR12 rate were 93.2% (95% CI 89.9%-95.9%, I(2) =0.0%), 
      89.4% (95% CI 82.0%-95.0%, I(2) =0.0%) and 94.7% (95% CI 91.0%-97.5%, I(2) =0.0%) 
      in total population, patients with sofosbuvir-based therapies and patients with 
      non-sofosbuvir-based therapies respectively. For HCV genotype 1 patients, the 
      pooled SVR12 rate was 93.1% (95% CI 88.3%-96.7%, I(2) =20.0%). The pooled 
      incidence of SAEs was 12.1% (95% CI 6.2%-19.7%, I(2) =55.0%). The pooled 
      discontinuation rate because of AEs or SAEs in our meta-analysis was 2.2% (95% CI 
      0.8%-4.4%, I(2) =0.0%). CONCLUSIONS: DAA-based antiviral therapies are effective 
      and well-tolerated for HCV patients with stage 4-5 chronic kidney disease.
CI  - (c) 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Li, Tao
AU  - Li T
AD  - Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong 
      University, Jinan, China.
FAU - Qu, Yundong
AU  - Qu Y
AD  - Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong 
      University, Jinan, China.
FAU - Guo, Ying
AU  - Guo Y
AD  - Department of Intensive Care Unit, The Second Hospital of Shandong University, 
      Jinan, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong 
      University, Jinan, China.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong 
      University, Jinan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20170102
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/adverse effects/pharmacokinetics/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genotype
MH  - Hepacivirus/*drug effects/genetics/growth & development
MH  - Hepatitis C/complications/diagnosis/*drug therapy/virology
MH  - Humans
MH  - Kidney/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Renal Insufficiency, Chronic/complications/diagnosis/*physiopathology
MH  - Severity of Illness Index
MH  - Sustained Virologic Response
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - direct-acting antiviral
OT  - hepatitis C virus infection
OT  - meta-analysis
OT  - stage 4-5 chronic kidney disease
EDAT- 2016/12/13 06:00
MHDA- 2018/04/10 06:00
CRDT- 2016/12/13 06:00
PHST- 2016/09/17 00:00 [received]
PHST- 2016/11/28 00:00 [accepted]
PHST- 2016/12/13 06:00 [pubmed]
PHST- 2018/04/10 06:00 [medline]
PHST- 2016/12/13 06:00 [entrez]
AID - 10.1111/liv.13336 [doi]
PST - ppublish
SO  - Liver Int. 2017 Jul;37(7):974-981. doi: 10.1111/liv.13336. Epub 2017 Jan 2.